Phase 1 N=23 Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
HIV Infection
Primary: Number of Participants With Adverse Events — 1; 2; 3; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=143 Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product
Visual Acuity
Primary: Clarity of Vision in Dim or Low Lighting — 54.3; 43.3; 33.3; 36.1 Percent
N/A N=31 Effectiveness of the Aeroneb in Acute Severe Asthma
Asthma Exacerbation
Primary: Percentage Change in Mean of Peak Expiratory Flow Rate (PEFR) Percentage of Predicted Baseline at 30 Minutes After the Initial Bronchodilator Treatment — 18.1; 12.9…
Phase 2 N=50 A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
Hyperhidrosis
Primary: Number of Treatment Emergent Adverse Events by Severity — 14; 4; 3; 0 Number of Events by Severity
N/A N=16 Measuring Comfort and Clarity With Low Gain Feature in Pediatric Hearing Aid Users
Hearing Loss
Primary: Speech Reception Threshold — 27; 27; 24; 24 dB HL (decibels hearing level) — p=<0.05
Phase 2 N=65 High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Multiple Myeloma
Primary: To Estimate the Response at Day 100 Following Transplant (Rate of CR) — 26; 32; 7 Participants
Phase 3 N=30 PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
Severe Uncontrolled Asthma
Primary: Clearance of Benralizumab — 0.156 liter (L) per day
Phase 4 N=42 Cryopreserved vs. Lyopreserved Stravix as an Adjunct to NPWT in the Treatment of Complex Wounds
Diabetic Wound
Primary: Complete Wound Closure — 4; 7 Participants
Phase 2 N=141 Flushing Reduction Associated With Nitrates
Menopausal Hot Flashes
Primary: Change From Baseline Hot Flash Frequency — -4.56; -4.02 Hot flashes per day — p=0.34
N/A N=8 Safety and Tolerability of Soy Fiber
Safety Issues · Tolerance
Primary: Number of Participants With Treatment-emergent Adverse Events Following Each Dose of Soy — 0; 1; 1 Participants
N/A N=8 Stream Segregation and Speech Recognition in Noise in Individuals With Cochlear Implants
Cochlear Implants
Primary: Speech Recognition — 62; 22 percentage of keywords correct
Phase 2 N=212 A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Pan Tumor
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A — 22.5; 38.6 Precentage of participants
Phase 2 N=164 Caring Light Project for Family Caregivers
Alzheimer Disease
Primary: Center for Epidemiological Studies Depression Scale — 17.72; 21.70 units on a scale
N/A N=24 Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
Treatment Resistant Depression
Primary: Change in Score on Child Depression Rating Scale - Revised (CDRS-R) — 12.33; 1.33; 22.13 score on a scale
Phase 2 N=143 A 6 Month Safety Extension Study of MBGS205
Hypogonadotropic Hypogonadism
Primary: Percent Change in Bone Mineral Density Measured by DEXA (g/cm^2) From Baseline in Study MBGS205 to Week 48 in Study MBGS206 — -2.24; -3.31; -1.68 Percentage change